Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 3.2 -1.84% -0.06
LXRX closed down 1.84 percent on Friday, October 18, 2019, on 40 percent of normal volume.

Earnings due: Oct 30

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical LXRX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -1.84%
Narrow Range Bar Range Contraction -1.84%
NR7 Range Contraction -1.84%
20 DMA Resistance Bearish -3.32%
Down 3 Days in a Row Weakness 0.00%
20 DMA Resistance Bearish -1.23%
Narrow Range Bar Range Contraction -1.23%
NR7 Range Contraction -1.23%
Fell Below 20 DMA Bearish -3.03%
20 DMA Support Bullish -5.04%

Older signals for LXRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Health Biopharmaceutical Life Sciences Pharmaceutical Industry Diabetes Drug Discovery Monoclonal Antibodies Clinical Trial Rheumatoid Arthritis Glaucoma Ulcerative Colitis Irritable Bowel Syndrome Treatment Of Glaucoma Biotie Therapies Genentech Human Disease
Is LXRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.33
52 Week Low 1.125
Average Volume 2,266,180
200-Day Moving Average 4.8966
50-Day Moving Average 2.4021
20-Day Moving Average 3.3243
10-Day Moving Average 3.337
Average True Range 0.3077
ADX 26.49
+DI 22.5523
-DI 18.3116
Chandelier Exit (Long, 3 ATRs ) 2.9269
Chandelier Exit (Short, 3 ATRs ) 3.7231
Upper Bollinger Band 3.6034
Lower Bollinger Band 3.0452
Percent B (%b) 0.28
BandWidth 16.791505
MACD Line 0.1668
MACD Signal Line 0.2327
MACD Histogram -0.0659
Fundamentals Value
Market Cap 338.82 Million
Num Shares 106 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -2.41
Price-to-Sales 13.10
Price-to-Book 9.99
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.46
Resistance 3 (R3) 3.47 3.39 3.41
Resistance 2 (R2) 3.39 3.33 3.39 3.40
Resistance 1 (R1) 3.30 3.29 3.26 3.29 3.38
Pivot Point 3.22 3.22 3.21 3.22 3.22
Support 1 (S1) 3.13 3.16 3.09 3.12 3.02
Support 2 (S2) 3.05 3.12 3.05 3.00
Support 3 (S3) 2.96 3.05 2.99
Support 4 (S4) 2.95